Evidence map›Paper›PMID 35606403›Full record

ArticleScientific reports2022

NANOG confers resistance to complement-dependent cytotoxicity in immune-edited tumor cells through up-regulating CD59.

Sung Wook Son, Eunho Cho, Hanbyoul Cho, Seon Rang Woo, Hyo-Jung Lee, Se Jin Oh, Suyeon Kim, Jae-Hoon Kim, Eun Joo Chung, Joon-Yong Chung and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 2 countries.

Sung Wook Son *Department of Cell Biology, Daegu Catholic University School of Medicine, Daegu, 42472, South Korea.
Eunho Cho *Department of Biochemistry and Molecular Biology, Korea University College of Medicine, Seoul, 02841, South Korea.
Hanbyoul ChoDepartment of Obstetrics and Gynecology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, 06273, South Korea.
Seon Rang WooDepartment of Biochemistry and Molecular Biology, Korea University College of Medicine, Seoul, 02841, South Korea.
Hyo-Jung LeeDepartment of Biochemistry and Molecular Biology, Korea University College of Medicine, Seoul, 02841, South Korea.
Se Jin OhDepartment of Biochemistry and Molecular Biology, Korea University College of Medicine, Seoul, 02841, South Korea.
Suyeon KimDepartment of Biochemistry and Molecular Biology, Korea University College of Medicine, Seoul, 02841, South Korea.
Jae-Hoon KimDepartment of Obstetrics and Gynecology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, 06273, South Korea.
Eun Joo ChungRadiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
Joon-Yong ChungMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
Min Gyu KimSchool of Medicine, The Catholic University of Korea, Seoul, South Korea.
Kwon-Ho SongDepartment of Cell Biology, Daegu Catholic University School of Medicine, Daegu, 42472, South Korea. khsong@cu.ac.kr.
Tae Woo KimDepartment of Biochemistry and Molecular Biology, Korea University College of Medicine, Seoul, 02841, South Korea. twkim0421@korea.ac.kr.
Korea University · KRDaegu Catholic University · KRCatholic University of Korea · KRGangnam Severance Hospital · KRNational Cancer Institute · USNational Institutes of Health · USYonsei University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer immunoediting drives the adaptation of tumor cells to host immune surveillance. Previously, we have demonstrated that immunoediting driven by cytotoxic T lymphocytes (CTLs) enriches NANOG

Indexed as

CD59 AntigensNeoplasmsApoptosisComplement System ProteinsHumansNanog Homeobox ProteinTrastuzumabTumor MicroenvironmentCD59 AntigensCD59 protein, humanComplement System ProteinsNanog Homeobox ProteinNANOG protein, humanTrastuzumab

Identifiers

PMID35606403
PMCPMC9126891
OpenAlexW4281293098

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.